Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.
复制标题
DOI：
10.1126/science.aah6157
复制
发表时间：
2016-09-09
期刊：
影响因子：
--
通讯作者：
Barouch DH
中科院分区：
文献类型：
--
作者：
Abbink P;Larocca RA;De La Barrera RA;Bricault CA;Moseley ET;Boyd M;Kirilova M;Li Z;Ng'ang'a D;Nanayakkara O;Nityanandam R;Mercado NB;Borducchi EN;Agarwal A;Brinkman AL;Cabral C;Chandrashekar A;Giglio PB;Jetton D;Jimenez J;Lee BC;Mojta S;Molloy K;Shetty M;Neubauer GH;Stephenson KE;Peron JP;Zanotto PM;Misamore J;Finneyfrock B;Lewis MG;Alter G;Modjarrad K;Jarman RG;Eckels KH;Michael NL;Thomas SJ;Barouch DH
寨卡病毒（ZIKV）是美洲正在发生的一场重大疫情的病原体，并且已被确定与胎儿小头畸形存在因果关联。因此，研发一种安全有效的寨卡病毒疫苗是全球卫生领域的当务之急。在此我们证明，三种不同的疫苗平台可保护恒河猴免受寨卡病毒攻击。一种纯化的灭活病毒疫苗可诱导产生寨卡病毒特异性中和抗体，并能完全保护猴子免受来自巴西和波多黎各的寨卡病毒株的感染。从接种疫苗的猴子体内提取的纯化免疫球蛋白在过继转移研究中提供了被动保护。一种质粒DNA疫苗以及一种单次注射的表达寨卡病毒prM - Env的重组恒河猴腺病毒52型血清载体也能引发中和抗体，并完全保护猴子免受寨卡病毒攻击。这些数据支持了寨卡病毒疫苗在人类中的快速临床研发。
Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector expressing ZIKV prM-Env also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.